76ers Star Joel Embiid Being Treated for 'Mild Case' of Bell’s Palsy, per Report

The All-NBA big man is coming off a 50-point performance in Game 3 against the Knicks.
Joel Embiid
Joel Embiid / Bill Streicher-USA TODAY Sports

The Philadelphia 76ers defeated the New York Knicks, 125–114, in Game 3 of their first-round playoff series Thursday night. Shortly after the game ended, ESPN's Adrian Wojnarowski reported superstar Joel Embiid was dealing with a medical condition for the last week.

After Embiid recorded 50 points to beat the Knicks, Wojnarowski reported he'd been receiving treatment for a "mild" case of Bell’s palsy for the last week. The news had yet to be reported because the center wanted to limit distractions during the postseason.

Embiid, per Wojnarowski, was wearing sunglasses for much of the last week because Bell's palsy impacts facial muscles on half of the face.

Here's what Embiid said about it after the game.

After his massive Game 3 outing, Embiid is averaging 37.6 points per game in 2024 NBA postseason play. He missed 29 straight games during February and March in the regular season due to a meniscus injury.

The 76ers' victory on Thursday night brought the series to 2–1. Philadelphia will attempt to even things up on Sunday in Game 4.


Published |Modified
Liam McKeone

LIAM MCKEONE

Liam McKeone is a Senior Writer for the Breaking & Trending News Team at Sports Illustrated. In addition to his role as a writer, he collaborates with other teams across Minute Media to help define his team’s content strategy. He has been in the industry as a content creator since 2017, and prior to joining SI in 2024, Liam worked for NBC Sports Boston and The Big Lead. In addition to his work as a writer, he has hosted the Press Pass Podcast covering sports media and The Big Stream covering pop culture. A graduate of Fordham University, Liam is always up for a good debate and enjoys loudly arguing about sports, rap music, books, and video games. Liam has been a member of the National Sports Media Association (NSMA) since 2020.